Computational Molecular Biology 2025, Vol.15, No.3, 131-140 http://bioscipublisher.com/index.php/cmb 139 Mannheimer J., Fowles J., Shaumberg K., Duval D., Prasad A., and Gustafson D., 2016, Predicting drug sensitivity based on gene array data for cytotoxic chemotherapeutic agents, Cancer Research, 76(14_Supplement): 1522-1522. https://doi.org/10.1158/1538-7445.AM2016-1522 Martin P., Leighl N., Tsao M., and Shepherd F., 2013, KRAS mutations as prognostic and predictive markers in non-small cell lung cancer, Journal of Thoracic Oncology, 8(5): 530-542. https://doi.org/10.1097/JTO.0b013e318283d958 Mitsudomi T., Kosaka T., and Yatabe Y., 2006, Biological and clinical implications of EGFR mutations in lung cancer, International Journal of Clinical Oncology, 11(3): 190-198. https://doi.org/10.1007/s10147-006-0583-4 Moossavi S., Fehr K., Moraes T., Khafipour E., and Azad M., 2020, Repeatability and reproducibility assessment in a large-scale population-based microbiota study: case study on human milk microbiota, Microbiome, 9(1): 41. https://doi.org/10.1101/2020.04.20.052035 Nguyen L., Dang C., and Ballester P., 2016, Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data, F1000Research, 5: ISCB Comm J-2927. https://doi.org/10.12688/f1000research.10529.2 Oh M., Park S., Lee S., Lee D., Lim S., Jeong D., Jo K., Jung I., and Kim S., 2020, DRIM: a web-based system for investigating drug response at the molecular level by condition-specific multi-omics data integration, Frontiers in Genetics, 11: 564792. https://doi.org/10.3389/fgene.2020.564792 Ohashi K., Sequist L., Arcila M., Morán T., Chmielecki J., Lin Y., Pan Y., Wang L., De Stanchina E., Shien K., Aoe K., Toyooka S., Kiura K., Fernandez-Cuesta L., Fidias P., Yang J., Miller V., Riely G., Kris M., Engelman J., Vnencak-Jones C., Dias-Santagata D., Ladanyi M., and Pao W., 2012, Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proceedings of the National Academy of Sciences, 109(31): E2127-E2133. https://doi.org/10.1073/pnas.1203530109 Reinhold W., Varma S., Rajapakse V., Luna A., Sousa F., Kohn K., and Pommier Y., 2015, Using drug response data to identify molecular effectors, and molecular omic data to identify candidate drugs in cancer, Human Genetics, 134(1): 3-11. https://doi.org/10.1007/s00439-014-1482-9 Shaffer S., 2022, Rare cell variability and drug resistance in cancer, Cancer Research, 82(10_Supplement): IA018. https://doi.org/10.1158/1538-7445.evodyn22-ia018 Shajahan-Haq A., Cheema M., and Clarke R., 2015, Application of metabolomics in drug resistant breast cancer research, Metabolites, 5(1): 100-118. https://doi.org/10.3390/metabo5010100 Sinke L., Cats D., and Heijmans B., 2021, Omixer: multivariate and reproducible sample randomization to proactively counter batch effects in omics studies, Bioinformatics, 37(18): 3051-3052. https://doi.org/10.1093/bioinformatics/btab159 Sun Z., Liu Y., Ouyang Q., Liu Z., and Liu Y., 2021, Research progress of omics technology in the field of tumor resistance: from single-omics to multi-omics combination application, Journal of Central South University (Medical Sciences), 46(6): 620-627. https://doi.org/10.11817/j.issn.1672-7347.2021.200561 Takamatsu S., and Matsumura N., 2023, Homologous recombination deficiency in the CCLE cell lines correlates with in vitro resistance to platinum agents and PARP inhibitors, Cancer Research, 83(7_Supplement): 2773-2773. https://doi.org/10.1158/1538-7445.AM2023-2773 Talwar J., and Carter H., 2020, Abstract 2099: Assessing cancer drug response prediction from gene expression, Clinical Research, 80(16_Supplement): 2099-2099. https://doi.org/10.1158/1538-7445.AM2020-2099 Tan X., Yu Y., Duan K., Zhang J., Sun P., and Sun H., 2020, Current advances and limitations of deep learning in anticancer drug sensitivity prediction, Current Topics in Medicinal Chemistry, 20(21): 1858-1867. https://doi.org/10.2174/1568026620666200710101307 Wang G., Liu X., Liu H., Zhang X., Shao Y., and Jia X., 2023, A novel necroptosis related gene signature and regulatory network for overall survival prediction in lung adenocarcinoma, Scientific Reports, 13(1): 15345. https://doi.org/10.1038/s41598-023-41998-2 Wang Z., Wu Y., Zhang G., Zhou Q., Xu C., and Guo A., 2008, EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients, Oncology Research and Treatment, 31(4): 174-178. https://doi.org/10.1159/000116736 Yamaguchi F., Kugawa S., Tateno H., Kokubu F., and Fukuchi K., 2012, Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy, Lung Cancer, 78(3): 201-206. https://doi.org/10.1016/j.lungcan.2012.08.014 Yang C., Liu Z., Dai P., Zhang Y., Huang P., Lin Y., and Xie L., 2022, Predicting tumor drug sensitivity with multi-omics data, Chinese Journal of Biotechnology, 38(6): 2201-2212. https://doi.org/10.13345/j.cjb.210676
RkJQdWJsaXNoZXIy MjQ4ODYzNA==